• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lexicon Pharmaceuticals, Inc. - Common Stock (NQ:LXRX)

    1.700 -0.060 (-3.41%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,458,137
    Open 1.780
    Bid (Size) 1.680 (1,000)
    Ask (Size) 1.700 (600)
    Prev. Close 1.760
    Today's Range 1.650 - 1.789
    52wk Range 0.2836 - 1.830
    Shares Outstanding 144,474,452
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
    – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – 
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +49.1%
    +49.1%
    1 Month
    +40.5%
    +40.5%
    3 Month
    +21.4%
    +21.4%
    6 Month
    +50.4%
    +50.4%
    1 Year
    +102.4%
    +102.4%

    More News

    Read More
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
    Via Chartmill
    News headline image
    Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Xpeng, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q3 2025 Earnings Surpass Expectations, Fueling Pre-Market Rally ↗
    Via Chartmill
    News headline image
    Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
    From Lexicon Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Lexicon Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Lexicon Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Lexicon Pharmaceuticals, Inc. - Common Stock trade on?
    Lexicon Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Lexicon Pharmaceuticals, Inc. - Common Stock is LXRX on the Nasdaq Stock Market
    What is the current price of Lexicon Pharmaceuticals, Inc. - Common Stock?
    The current price of Lexicon Pharmaceuticals, Inc. - Common Stock is 1.700
    When was Lexicon Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Lexicon Pharmaceuticals, Inc. - Common Stock was at 01/23/26 04:00 PM ET
    What is the market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Lexicon Pharmaceuticals, Inc. - Common Stock is 245.61M
    How many shares of Lexicon Pharmaceuticals, Inc. - Common Stock are outstanding?
    Lexicon Pharmaceuticals, Inc. - Common Stock has 246M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.